Carcinoma, Hpatocellular
Conditions
Brief summary
This observational study investigates the association between serum Omega-6 fatty acids and hepatocellular carcinoma development. Adult HCC patients and age - and gender matched healthy controls will be included. Serum Omega-6 levels will be compared between groups to explore potential correlations with disease presence and severity .
Detailed description
Hepatocellular carcinoma is a leading cause of cancer related deaths worldwide . Omega-6 fatty acids have been suggested to influence liver cancer development .This observational study aims to assess the association between serum Omega-6 fatty acid levels and HCC development . Adult patients diagnosed with HCC will be recruited from Sohag University Hospital, along with age and gender matched healthy controls . Blood samples will be collected to measure serum Omega-6 levels using standardized bio-chemical assays . clinical and laboratory data , including liver function tests and tumor stage , will also be recorded. The study will compare Omega-6 levels between HCC patients and controls , and analyze potential correlation with disease severity .Findings may provide insights into the role of Omega-6 fatty acids in HCC pathogenesis and help identify biomarkers for early detection and risk assessment .
Interventions
DIETARY_SUPPLEMENTOmega 6 fatty acid
Participants will receive an oral Omega-6 fatty acid dietary supplement in capsule form. The supplement will be administered once daily with meals for a total duration of 8 weeks. Each capsule contains a standardized dose of omega -6 fatty acids, and participants will be instructed to maintain their usual diet during the study period . compliance will be monitored though follow up visits and capsule count . no additional supplements containing omega fatty acids will be allowed during the intervention period .
Sponsors
Sohag University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* 1\. Adults aged 18 years and above. 2. Patients with hepatocellular carcinoma (confirmed clinically, laboratory, radiologically, or histopathologically). 3\. Ability and willingness to provide informed written consent. 4. For healthy controls: individuals without liver disease or history of malignancy, matched by age and gender. 5\. For cirrhotic controls: patients with liver cirrhosis without evidence of any malignancy, matched by age and gender.
Exclusion criteria
1. History of chronic inflammatory (except for liver cirrhosis or HCC) or autoimmune diseases. 2. Current use of omega-6 or omega-3 fatty acid supplements. 3. Presence of other types of cancer. 4. Pregnant or lactating women. 5. presence of severe comorbid condition. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum Omega-6 Fatty Acid Levels | At baseline | Measurement of circulating levels of Omega-6 fatty acids in blood samples of hepatocellular carcinoma patients and healthy controls using standardized laboratory techniques. The primary outcome will assess the association between serum Omega-6 concentrations and the presence of hepatocellular carcinoma. |
Contacts
Primary Contactmariam maher, Resident doctor
Outcome results
None listed